ESC Professional Premium Access

Sacubitril/valsartan treatment: effect on left ventricular remodelling and fibrosis assessed by novel heart failure biomarkers

Congress Session

About the speaker

Mrs Ainhoa Robles Mezcua

Virgin of Victory University Hospital, Malaga (Spain)
2 presentations
0 follower

7 more presentations in this session

Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan

Speaker: Assistant Professor A. Giannoni (Pisa, IT)

Thumbnail

Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?

Speaker: Doctor G. Oliveira Campos (Coimbra, PT)

Thumbnail

Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Bielecka-Dabrowa (Lodz, PL)

Thumbnail

Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Hernandez (Storrs, US)

Thumbnail

Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)

Speaker: Assistant Professor K. Lee (Incheon, KR)

Thumbnail

Access the full session

Heart failure pharmacotherapy - Sacubitril/valsartan

Speakers: Mrs A. Robles Mezcua, Assistant Professor A. Giannoni, Doctor G. Oliveira Campos, Professor A. Bielecka-Dabrowa, Professor A. Hernandez...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk